Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-08-31
2010-11-09
Pak, Michael (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07829298
ABSTRACT:
The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.
REFERENCES:
patent: 5514578 (1996-05-01), Hogness et al.
patent: 5532157 (1996-07-01), Fink
patent: 5573944 (1996-11-01), Kirschner et al.
patent: 5639616 (1997-06-01), Liao et al.
patent: 5750353 (1998-05-01), Kopin et al.
patent: 5861309 (1999-01-01), Bard et al.
patent: 5891720 (1999-04-01), Moore et al.
patent: 5955308 (1999-09-01), Bergsma et al.
patent: 2002/0137063 (2002-09-01), Glucksmann et al.
patent: 2003/0078218 (2003-04-01), Jarai et al.
patent: 2003/0171541 (2003-09-01), Elliott et al.
patent: 2135253 (1996-05-01), None
patent: 100 21 475 (2001-11-01), None
patent: 100 21 475 (2001-11-01), None
patent: 0 612 845 (1994-08-01), None
patent: 0 878 542 (1998-11-01), None
patent: 0 892 051 (1999-01-01), None
patent: 1 090 989 (2001-04-01), None
patent: 1 094 076 (2001-04-01), None
patent: 0109028.1 (2001-05-01), None
patent: 0126637.6 (2002-01-01), None
patent: 2 365 868 (2002-02-01), None
patent: 2365868 (2002-02-01), None
patent: 11-32770 (1999-02-01), None
patent: 8-245697 (1999-09-01), None
patent: 11-98988 (1999-09-01), None
patent: WO 96/05302 (1996-02-01), None
patent: WO 97/11159 (1997-03-01), None
patent: WO 97/21731 (1997-06-01), None
patent: WO 98/00552 (1998-01-01), None
patent: WO 98/29439 (1998-07-01), None
patent: WO 98/34948 (1998-08-01), None
patent: WO 98/38217 (1998-09-01), None
patent: WO 98/46620 (1998-10-01), None
patent: WO 98/46995 (1998-10-01), None
patent: WO 98/56820 (1998-12-01), None
patent: WO 99/06552 (1999-02-01), None
patent: WO 99/24569 (1999-05-01), None
patent: WO 99/32519 (1999-07-01), None
patent: WO 99/48921 (1999-09-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/14229 (2000-03-01), None
patent: WO 00/22129 (2000-04-01), None
patent: WO 00/22131 (2000-04-01), None
patent: WO 00/49046 (2000-08-01), None
patent: WO 01/07606 (2001-02-01), None
patent: WO 01/09184 (2001-02-01), None
patent: WO01/12673 (2001-02-01), None
patent: WO 01/14577 (2001-03-01), None
patent: WO 01/16159 (2001-03-01), None
patent: WO 01/31014 (2001-05-01), None
patent: WO 01/36471 (2001-05-01), None
patent: WO 01/36473 (2001-05-01), None
patent: WO01/36476 (2001-05-01), None
patent: WO 01/36476 (2001-05-01), None
patent: WO01/61359 (2001-05-01), None
patent: WO 01/61359 (2001-05-01), None
patent: WO 01/73029 (2001-10-01), None
patent: WO01/73029 (2001-10-01), None
patent: WO 01/74904 (2001-10-01), None
patent: WO01/74904 (2001-10-01), None
patent: WO01/77320 (2001-10-01), None
patent: WO 01/77320 (2001-10-01), None
patent: WO 01/87937 (2001-11-01), None
patent: WO01/87937 (2001-11-01), None
patent: WO 01/94385 (2001-12-01), None
patent: WO01/94385 (2001-12-01), None
patent: WO02/13845 (2002-02-01), None
patent: WO 02/13845 (2002-02-01), None
patent: WO 02/18579 (2002-03-01), None
patent: WO 02/18579 (2002-03-01), None
patent: WO 02/18938 (2002-03-01), None
patent: WO02/18938 (2002-03-01), None
patent: WO 02/072755 (2002-09-01), None
patent: WO 02/083736 (2002-10-01), None
patent: WO 02/084298 (2002-10-01), None
patent: WO02/084298 (2002-10-01), None
patent: 2008063321 (2008-05-01), None
U.S. Appl. No. 10/484,788.
Alla et al., “Extracellular domains of the bradykinin B2 receptor involved in ligad binding and agonist sensing defined by anti-peptide antibodies,”J. Biol. Chem., 1996, vol. 271, pp. 1748-1755.
Advenier et al., “Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK2) receptors,”Am. Rev. Respir. Dis., 1992, vol. 146 (5, pt. 1), pp. 1177-1181.
Alexander et al., “Point mutations within the dimmer interfact homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity,”EMBO J., (1995) 14(22):5569-5578.
Arvanitikis et al., “Human herpesvirus KSHV encodes a constitutively active G-protein coupled receptor linked to cell proliferation,”Nature, (1997) 385:347-349.
Barker et al., “Constitutively active 5-hydroxytryptamine2creceptors reveal novel inverse agonist activity of receptor ligands,”J. Biol. Chem. (1994) 269(16):11687-11690.
Baxter, “5-HT2receptors: a family re-united?”Trends Pharmacol. Sci., 1995, 16:105-110.
Besmer et al., “A new acute transforming feline retrovirus and relationship of its oncogene v-kitwith the protein kinase gene family,”Nature, (1986) 320:415-421.
Blin et al., Mapping of single amino acid residues required for selective activation of G11by the m3 muscarinic acetylcholine receptor,J. Biol. Chem. (1995) 270:17741-17748.
Bond et al., “Inverse agonists and G-protein-coupled receptors,”Receptor-Based Drug Design, 1988, pp. 363-377.
Boone et al., “Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype,”Proc. Natl. Aca. Sci. USA, (1993) 90(21):9921-9925.
Burstein et al., “Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectively domains,”Biochem. Phrmacol., (1996) 51(4):539-544.
Burstein et al., “Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop,”J. Biol. Chem. (1996) 271(6):2882-2885.
Burstein et al., “Constitutive activation of muscarinic receptors by the G-protein Gq,”FEBS Lett. (1995) 363(3):261-263.
Bylund, “International union of pharmacology nomenclature of adrenoceptors,”Pharmacol. Rev. (1994) 45:121-136.
Casey et al., “Constitutively active mutant 5-HT2Aserotonin receptors: inverse agonist activity of classical 5-HT2Aantagonists,”Soc. Neurosci, (1996) Abstract #699.10.
Cheatham et al., “Substitution of theerbB-2 oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin-receptor substrate 1,”Proc. Natl. Acad. Sci. USA, (1993) 90:7336-7340.
Chen et al., Tethered ligand library for discovery of peptide agonists,J. Biol.Chem. (1995) 270:23398-23401.
Chen et al., “Microbial hydroxylation and glucuronidaton of the angiotesin II (AII) receptor antagonist MK 954,”J. Antibiot. (1993) 46(1):131-134.
Chen et al., “A colorimetric assay for measuring activation of Gs- and Gq-coupled signaling pathways,”Anal. Bochem. (1995) 226(2):349-354.
Chidiac et al., “Inverse agonist activity of beta-adrenergic antagonists,”J. Pharm. Exp. Ther., (1994) 45:490-499.
Clozel et al., “In vivo pharmacology of Ro 46-2005 , the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology,”J. Cardiovas. Pharmacol., (1993) 22(Suppl. 8):S377-S379.
Collessi et al., “A splicing variant of theRONtranscript induces constitutive trosine kinase activity and an invasive phenotype,”Mol. Cell. Biol. (1996) 16(2):5518-5526.
Cooper et al., “Molecular cloning of a new transforming gene from a chemically transformed human cell line,”Nature, 1984, 311:29-33.
De Dios et al., “Effect of L-364,718 (CCK Receptor Antagonist) on exocrine pancreatic secretion of hydrocortisone-treated rats,”Pancreas, 1994, 9(2):212-218.
Desbois-Mouthon et al., “Deletio
Behan Dominic P.
Chalmers Derek T.
Chen Ruoping
Choi Bryan J.
Connolly Daniel T.
Arena Pharmaceuticals Inc.
Bozicevic Field & Francis LLP
Pak Michael
Scherer David C.
LandOfFree
Human G protein-coupled receptors for metabolic-related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human G protein-coupled receptors for metabolic-related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human G protein-coupled receptors for metabolic-related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248810